Q32 Bio IncQTTB
▼ NegativeCapitalrelevance
Company is conducting a dilutive public offering of 6.03M shares plus pre-funded warrants, raising ~$200M but diluting existing shareholders.
Impact on stocks 1
Biotech & Genomic Medicine
Q32 Bio IncQ32 Bio has priced an underwritten public offering expected to raise approximately $200 million in gross proceeds. The clinical-stage biotechnology company is offering 6.03 million shares of common stock at $18.25 per share and, in lieu of common stock for certain investors, pre-funded warrants to purchase 4.93 million shares at $18.2499 each. The proceeds estimate assumes no exercise of the underwriters' 30-day option to purchase up to an additional 1.64 million shares. The offering is expected to close on July 16, with net proceeds used for working capital including research, clinical development and commercialization activities, focusing on advancing bempikibart into future clinical trials. The stock price increased about 2.6% on Tuesday during after-hours trading.
Q32 Bio IncCompany is conducting a dilutive public offering of 6.03M shares plus pre-funded warrants, raising ~$200M but diluting existing shareholders.